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Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy
(SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as
ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients
with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are
delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing–
related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node
(LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and
abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year
actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects
are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In
conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal
oligometastases.
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Stereotactic Body Radiation Therapy (SBRT) was devel-
oped in the wake of Intracranial Stereotactic Radiosurgery
(SRS) and Fractionated Stereotactic Radiotherapy (SRT) as
a result of technological advances made in the early 1990’s
in tumour motion quantification and image guidance [1].
Stereotaxy is a form of neurosurgery that uses a mechan-
ical head frame and a precise 3-dimensional (3D) coordin-
ate system to align and direct surgical instruments. SRT
uses the methods of stereotactic neurosurgery to locate
and target malignant and benign brain lesions before the
delivery of radiation therapy [2].
In 1994, Lax et al. in Sweden applied this 3D ap-
proach to the targeting of extracranialtumours [3].
They constructed a combined body frame-abdominal
compressing device and devised a method for the
placement of external fiducial markers that could be
indexed to the internal target. In 1998, Uematsu et al.
developed a frameless “focal unit” which combines a* Correspondence: emmanuel.rio@ico.unicancer.fr
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distribution, and reproduction in any mediumlinear accelerator (Linac), computed tomography (CT)
scanner, and X-ray simulator (X-S) [4]. Treatment of 66
primary and metastatic lung carcinomas by this technique
resulted in only 2 cases of local progression.
SBRT is a superior “focal unit” combining hypofractio-
nated multi-beam conformal radiotherapy (CRT) and
image-guided radiotherapy (IGRT). It delivers a high radi-
ation dose, divided into several fractions (“hypofractio-
nated”), to extracranial lesions. It is a high- precision
technique with tight planning margins and a sophisticated
treatment plan allowing rapid dose fall-off away from the
treatment area. It provides improved volume targeting and
smaller irradiated volumes of normal tissue. Its use is usu-
ally limited to well-circumscribed tumours (maximum
cross-sectional diameter of up to 5 cm) but tumours as
large as 7 cm have been treated. Low isodoses (e.g. 80% iso-
dose) are often prescribed due to dose heterogeneity within
the target [5]. Its exact definition can, however, vary.
SBRT use was initially confined to patients with unre-
sectable or medically inoperable tumours. Nowadays,
however, its use has been extended to patients with resect-
able or medically operable tumours. Results are encour-
aging in the treatment of lung and liver metastases butntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(LN) and adrenal gland. Provided that dosimetric con-
straints are met, SBRT is well tolerated.
Oligometastases are metastases that are limited in num-
ber and location. Hellman and Weichselbaum coined this
term in 1995 [6]. They hypothesised that patients with less
aggressive tumours and few new metastases during the
first 4 months of first metastatic progression could poten-
tially benefit from metastasis-directed therapy. They also
identified a class of small RNAs, known as microRNAs,
which might help distinguish patients with stable oligome-
tastatic disease from patients with progression to polyme-
tastatic disease. Oligometastases produced by early
progression of primary lesions are known as de novo “oli-
gometastases” whereas widespread metastases correspond
to a state of “induced oligometastases” [7].
The aim of SBRT is to achieve good local control (LC)
of each oligometastatic site and possibly the cure of some
patients. Careful patient selection is needed. The best can-
didates for SBRT are patients with controlled primary
tumours (colon or breast, sarcomas, kidney carcinomas), 4
or fewer oligometastatic sites, oligometastases < 5 cm,
younger age, and good performance status [1].
This review will present the emerging role of hypofrac-
tionated SBRT in treating oligometastases to abdominal
organs and lymph nodes.
Biology of hypofractionated SBRT and oligometastases
Experimental work has suggested that the greater efficacy
of hypofractionated high-dose SBRT over normofrac-
tionated RT in the treatment of radioresistanttumours
might be due to different effects on both tumour and
normal cells.
Radiation-induced cell death has been modelled
according to the linear-quadratic (LQ) model which pos-
tulates that multiple radioinduced lesions interact in the
cell to trigger cell killing. This assumption is described
by the equation: S = e-(aD+ bD2). The model is widely
used in RT to calculate isoeffect doses for different.
According to the LQ model, high-dose fractions are
needed to enhance tumour cell death. Treatment plan-
ning margins must therefore be small in order to reduce
the total volume of normal tissue within the radiation
field and to minimise late adverse effects, and the inter-
val between fractions must enable complete repair of
normal tissues. The LQ model is a reliable and mechan-
istically plausible model for designing protocols in the
2–10 Gy dose per fraction range. A loss in accuracy is
expected above 10 Gy but, according to animal data, the
model remains acceptable for designing clinical trials up
to a 15–18 Gy dose per fraction [8].
The concepts underlying the damaging effects of ionising
radiation on normal tissue architecture were introduced in
the 1980’s [9,10]. Basically, organs are divided into twotypes according to their response to RT: (i) parallel func-
tioning organs are made up of functional subunits that act
independently (lung, liver, kidneys, and glandular tissues
beyond the major ducts); (ii) serial functioning organs are
made up of functional subunits that act in cooperation
(bowels, bronchi, large ducts in glands, blood vessels, and
nerves). SBRT can cause profound late adverse effects if
delivered near serially functioning tissues [1].
The biologically most significant mechanism under-
lying radiation-induced damage in tumours and nor-
mal tissue is generally thought to be clonogenic cell
death due to radioinduced DNA double-strand breaks
(DSBs). Recently, however, ceramide-induced endothe-
lial apoptosis rather than DNA DSB-induced clono-
genic cell death has been considered to underlie the
effects of hypofractionated SBRT [11]. Protection of
endothelial cells against apoptosis induced by exposure
to clinically relevant radiation doses is given by basic
fibroblast growth factor (bFGF), and this natural pro-
tection mechanism may be associated with radiation
resistance in normal and malignant tissues in vivo [12].
An immune-mediated mechanism might also contrib-
ute toward better survival outcomes for SBRT than
conventional RT.
Experimental work has shown that ablative RT (15–
25 Gy × 1) alone generates strong enough CD8+ T
cell–dependent immunity to lead to tumour reduc-
tion, reduced relapse of primary tumour, and even
eradication of metastasis in some settings [13], thus
bringing current intensive RT/chemotherapy protocols
into question. Finally, microRNAs may play a key
role. A study of 42 tumour samples from oligometa-
static patients treated with high-dose RT found that
microRNA-200c expression enhancement in an oligo-
metastatic cell-line resulted in polymetastatic progres-
sion [14]. The radiobiology of high-dose RT delivered
to oligometastases is a field of intensive study.
The SBRT procedure
SBRT has to overcome four hurdles: (i) patient position-
ing, (ii) internal organ motion, (iii) target volume shrink-
age or expansion and (iv) subclinical malignant
involvement not identifiable on the images available at
treatment planning [15]. Proper patient positioning, tar-
get localisation, and management of breathing–related
motion are essential to ensure the tight planning mar-
gins of SBRT. SBRT uses a wide variety of imaging tech-
niques to delineate lesions and in dose calculations, of
patient immobilisation and positioning devices to ensure
safety and reliability, and of image guidance systems
(Table 1) [5,16]. Recent SBRT-ready machines integrate
several state-of-the-art RT capabilities (IGRT and immo-
bilisation and respiratory motion solution technology)
into a single machine.
Table 1 Components of SBRT
Component Some examples
Imaging General radiography; 3- or 4-Dimensional Computed Tomography (CT); Magnetic
Resonance Imaging (MRI); Magnetic Resonance Spectroscopy (MRS); Positron Emission
Tomography (PET) with or without image fusion with other techniques
Patient immobilisation and positioning Stereotactic Body Frame™ (Elekta, USA); BodyFix™ (Medical Intelligence, Germany)
Image guidance SonArray™modular ultrasound unit (Zmed, Ashland, USA); ExacTrac™ Ultrasound
Localisation (BrainLAB, USA); BAT™ system (Nomos, USA).
SBRT-ready machines Novalis™, BrainLAB, USA; Electa’s Synergy™; Varian’s Triology™; Tomotherapy’sHiArt
(Tomotherapy, USA); Cyberknife™ (Accuray, USA), VERO-SBRT™ (Germany).
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Tumour Volume (GTV) is outlined in each slice where
the lesion appears. A Clinical Target Volume (CTV) is
applied to account for microscopic extension of the le-
sion although, in the case of metastases, the CTV and
GTV are considered equal. The final Planning Target
Volume (PTV) has even larger margins (≤10 mm) in
order to correct for inaccuracies in the delivery system
[17,18]. In general the PTV is encompassed by the
65-95% isodose line. SBRT may use a single treatment
fraction (“radiosurgery”) or up to 10 fractions (“hypo-
fractionated” SBRT).
Most reports on SBRT delivered by a gantry-operated
linear accelerator mention the use of a method of mo-
tion management at planning and/or treatment. A var-
iety of methods are used: (i) addition of constraints to
the immobilisation device (e.g. dual vacuum technology
for Medical Intelligence’s BodyFix™, a diaphragm control
device for Elekta’s Stereotactic Body Frame™), (ii) use of
tracking devices with fiducial markers implanted near
the target volume (e.g. Cyberknife™, BrainLabExacTrac™),
(iii) Gated Radiotherapy (GRT). Internal fiducial markers
are used to track tumour motion in real-time during
treatment but can cause artefacts on the images used for
treatment planning. Although SBRT is considered to be
non-invasive, these markers are implanted percutan-
eously under CT- or ultrasound-guidance. Their purpose
is to reduce internal organ motion to < 5 mm.
The efficacy of GRT was first established on treatment
of tumours located close to the diaphragm [19]. In GRT,
devices that monitor breathing trigger radiation delivery
during specific phases of the respiratory cycle, or the ra-
diation beam is continuously turned on and off to
synchronize delivery with the respiration cycle. Patients
can breathe freely (e.g. Varian’s Real-time Position Man-
agement™ (RPM) system) or a pause in breathing can be
induced either by an occlusion valve operated by the
clinician (e.g. Elekta’s Active Breathing Coordinator™
(ABC)) or voluntarily by the patients themselves (deep
inspiratory breath hold (SpiroDynr’X™, France). A
breath-hold device is used with single-shot echo-planar-
imaging (EPI) but also with other types of IGRT such as
3D-CBCT.Geometrical uncertainties, which can be machine related
(e.g. laser misalignment) or patient related (e.g. target
volume definition, setup errors, organ motion), are handled
by applying safety margins (Table 2) [20-25]. In addition,
basing nodal RT portals on vascular rather than bony
anatomy can significantly reduce normal tissue irradiation
[26]. IGRT enables automatic correction of patient
position through translation and rotation of the treat-
ment couch on based measurements provided by the
imaging system [27]. The most common image guid-
ance system used to obtain volumetric information on
patient geometry is 3D-cone-beam-CT (CBCT). It has
become standard equipment on many modern linear
accelerators.
Biological image-guidance and dose-painting are two
developments that have been combined with SBRT to
customise treatment. However, they have not yet been
validated for SBRT of oligometastases. Ling et al.
hypothesised that “biological” images revealing meta-
bolic, functional, and physiological activity can be used
to derive a biological target volume (BTV) in order to
incrementally improve target delineation and dose deliv-
ery [28]. For example, image fusion between MRI and
FDG-PET/CT in a simulator is used to identify hyper-
metabolic activity areas and microscopic disease exten-
sion. MRI tends to be used for imaging of liver
oligometastases and PET for imaging of abdominal LN
and adrenal oligometastases. Fluoro-D-glucose (FDG)-
PET/CT use is hampered, in the case of liver oligome-
tastases, by breathing-related motion and physiological
FDG uptake by the liver and, in the case of abdominal
oligometastases, by peristalsis movements of the intes-
tine. Dose-painting radiotherapy (DPRT), which makes
use of PET-CT with tracers other than FDG (fluoromi-
somidazole (Fmiso) or fluroro-L-thymidine (FLT)) or
dynamic contrast enhanced (DCE)-MRI, delivers a higher
dose to the most radioresistant areas of the tumour and
reduces the dose to the most sensitive areas [29].
Although practice guidelines on SBRT have been issued
by the American Society for Therapeutic Radiology and
Oncology (ASTRO) and the American College of Radiology
(ACR), wide variations persist among centers in prescrip-
tion patterns and treatment delivery systems [16].
Table 2 Advocated safety margins
Team Metastases Recommendation
Schefter et al. 2005 [20] SBRT of liver metastases Minimum distance between GTV and PTV surfaces:
— 0.5 cm, axial planes
— 1.0 cm, superior/inferior
Cumulative maximum tumourdiameter: < 6 cm
Katria et al. 2010 [21] IGRT of abdomen and pelvis Stroom's and Van Herk's margins (cm):
— 0.39 and 0.35 mm, anterior-posterior
— 0.94 and 0.46 mm, medial-lateral
— 0.40 and 1.09 mm, superior-inferior
Wysocka et al. 2010 [22] Median 3.8 mm intrafraction craniocaudal displacement
for coeliac axis with smaller displacements for other axes
RTOG consensus guidelines [23] Inguinal lymph nodes Caudad extent of the inguinal region : 2 cm to the
saphenous/femoral junction
Kim et al. 2011 [24] Inguinal and femoral nodes 2.2 - 2.9 cm around femoral vessels
Van Weieringen et al. 2011 [25] Pelvic lymph nodes For offline and online correction protocols, respectively:
— 7 and 5 mm, left-right
— 6 and 5 mm,craniocaudal
— 8 and 7 mm,dorsoventral
RTOG: Radiation Therapy Oncology Group.
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SBRT of oligometastases
Most published work on SBRT use in oligometastatic
abdominal disease concerns liver metastases rather than
abdominal lymph nodes or adrenal gland metastases.
The following summary of clinical trials is based on a
systematic Medline search (languages: English & French;
key-words: “stereotactic”, “radiotherapy”, “cancer: metas-
tases, oligometastases”, “liver”, “abdominal lymph
nodes”, “adrenal gland”, “extracranial”, “surgery”; publi-
cation types: original articles and reviews; dates: 1995 to
Nov 2010; updated in Mar. 2012 and of a manual search
of cited references, selected journals, and abstracts of
international congresses (ESTRO2010, ASTRO2010 and
ASTRO2011). Preferential article selection criteria were
as follows: (i) for SBRT of liver metastases: prospective
trials reporting actuarial local control (LC) in ≥20 lesions
after treatment with ≤5 SBRT fractions, as well as trials
on primary liver cancer and oligometastases, (ii) for
SBRT of abdominal LN and adrenal gland metastases: all
available prospective and retrospective studies trials. Be-
cause of marked variations in the reporting of doses and
outcomes among studies, a unified analysis was not
possible.
SBRT of liver oligometastases
The liver is a common metastatic site for a variety of pri-
mary malignancies including colorectal, lung, breast, blad-
der, oesophageal, head & neck and pancreatic cancers, and
cholangiocarcinoma. According to the most recent version
of the National Comprehensive Cancer Network (NCCN)guidelines (v.3.2012), surgical resection is still the standard
of care for liver metastases. However, despite the
favourable outcomes that have been reported after surgery
[30,31], 80-90% of patients are either patients with lesions
that are surgically not resectable or are medically inoper-
able patients at the time of diagnosis [32].
The first radiotherapeutic modality used to treat liver
metastases was Whole Liver RT (WLRT) [33]. Results
were encouraging but radiotherapy regimens of 32 Gy in
16 fractions or more were insufficient to eradicate dis-
ease and were often associated with radiation-induced
liver disease (RILD). RILD is a clinical syndrome of anic-
teric hepatomegaly, ascites, and elevated liver enzymes
occurring within 3 months after completion of therapy.
Attempts to increase the efficacy of WLRT proved un-
satisfactory [34] and led to the development of Partial
Liver Radiation Therapy (PLRT). Low-dose WLRT
nevertheless remains a useful treatment for symptom
palliation in patients with end-stage cancer and diffuse
metastatic infiltration of the liver which has become re-
fractory to systemic treatment [35]. Outcomes for PLRT,
which is usually a non-targeted therapy, were better than
for WLRT but not lasting. The 6-month actuarial LC of
62% for PLRT is, however, far below the most recent LC
rates recorded for SBRT [36].
Compared to WLRT and PLRT, SBRT has the advan-
tage of delivering higher tumoricidal doses to the target
and sparing uninvolved liver and surrounding critical
organs, thus diminishing the likelihood of RILD. SBRT
provides more accurate radiation delivery, meets the
normal tissue constraints better (Table 3) [37,38], and
Table 3 Recommended dose constraints to the liver
Whole-liver RT (WLRT) Partial liver RT (PLRT) Stereotactic body radiation RT (SBRT)
≤ 30 Gy, 2 Gy/fraction < 32 Gy, 2-Gy/fraction < 15 Gy in 3 fractions
21 Gy in 7 fractions At least 10% of normal liver spared from radiation < 20 Gy in 6 fractions
≥ 700 mL of normal liver receives≤ 15 Gy
3 to 5 fractions
Almaghrabi et al. Radiation Oncology 2012, 7:126 Page 5 of 10
http://www.ro-journal.com/content/7/1/126has a smaller PTV margin. The initial LC rate for SBRT
of liver metastases was 80% back in 1995 [39]. However,
the latest reports withbetter patient selection show
higher efficacy and lower toxicity as well as improved
outcomes from advances in multimodality-imaging.
Patient selection
Strict selection of patients is required to limit normal
tissue toxicity to intra-abdominal organs including the
liver, stomach, and duodenum. For inclusion in our sys-
tematic review, patients had to present no more than 3
metastases; no lesion >6 cm; no lesion immediately adja-
cent to the GI tract (distance >6 mm) in radiosurgery
patients; and adequate pre-treatment baseline liver func-
tion. The RT regimen had to be ≤ 5 fractions of radi-
ation, with ≥700 mL of normal liver receiving ≤15 Gy
(for 3 fractions) or at least 700 mL for a cumulative dose
of 21 Gy (for 5 fractions). GTV was expanded by 5–
10 mm to yield the PTV. These criteria for radiation
dose, however, are not derive from validated guidelines
but are suggestions based on radiobiological modelling
or expert opinion.
On applying these selection criteria, we retrieved 10
prospective studies with a wide variety of doses and
schedules (Table 4) [40-49]. The highest total dose per




Herfarth et al. 2001 [40] 56 14-26× 1
Wulf et al. 2001 [41] 23 30× 3
Wulf et al. 2006 [42]. 51 variable do
Hoyer et al. 2006 [43] 97/141*lesions 45× 3
Méndez-Romero et al. 2006 [44] 34 37.5× 3
Kavanagh et al. 2006 [45]. 36 60× 3
Milano et al. 2008 [46]. 120/293*lesions 50× 5
Rusthoven et al. 2009 [47]. 63 36 - 60× 3
Van der Pool et al. 2010 [48] 31 37.5 - 45×




* Ratio of liver oligometastases to total number of oligometastases.3 (range, 1 to 5). Centrally located lesions might require
delivery of the highest number of fractions because of
the proximity of critical structures [49].
Local control and follow-up
Dose escalation, tested by 4 institutions, was associated
with improved LC and median survival rates. For liver
SBRT as for lung SBRT, a higher radiation dose and a
smaller GTV were significant predictors of better LC in
univariate analyses. The 3-year actuarial LC rate was
89.3% for a nominal dose of ≥54 Gy compared to 59.0%
for a 36–53.9 Gy dose and 8.1% for a <36 Gy dose [50].
Among the 10 selected trials in Table 4, doses ≥54 Gy
were administered in 2 trials. Kavanagh et al. recorded
LC rates of 100% and 93% at 1 and 2 years in 36 patients
with liver metastases receiving 60 Gy in 3 fractions. Rule
et al. observed excellent LC in their 60-Gy cohort, with
no failures at 1 or 2 years. Poorer LC was recorded in
trials using doses < 36 Gy (3 fractions) or 20 Gy (radio-
surgery) [40,42]. Poorer LC was associated with a greater
GTV. The 2-year LC rate was 100% for ≤3 cm lesions
compared to 77% for >3 cm lesions (P = 0.015, log-rank
test) [47]. In a study of 293 lesions, multivariate analysis
revealed a significant association between colorectal me-
tastases and multiple local failure [46], but prior chemo-
therapy might account for this unconfirmed observationfr) Median follow
up (mos)
Actuarial LC rate (%)
at 12 mos at 24 mos
6 75
9 76 61
se× (1–3) 15 92 66
4.3 years 79
13 100 86
19 93 (at 18 mos)
41 67
16 95 92




Almaghrabi et al. Radiation Oncology 2012, 7:126 Page 6 of 10
http://www.ro-journal.com/content/7/1/126[49]. Overall, the foregoing findings suggest that patients
with oligometastases ≤ 3 cm and who receive doses of
60 Gy might be most likely to achieve long-term control.
Follow-up of patients after liver SBRT is a challenge as
the early treatment response (before 3 months) may be
difficult to interpret on CT or MRI images because of a
reaction to radiation. This reaction may be a form of
veno-occlusive disease but is not associated with changes
in overall liver function. Changes in contrast enhanced
CT-scans were observed in all 44 patients of the Wulf
et al. study after fractionated treatment with a cumula-
tive 20 Gy-isodose [42].
LC after SBRT of liver oligometastases is sustained. A
median time to maximal response of 6 months and a 71%
LC rate (95% confidence intervals, 58–85) were reported
in a Phase I study of 68 patients receiving 41.8 Gy (range,
27.7 to 60 Gy) [42]. A PET scan obtained at 13 months
post-SBRT in an interim analysis of a Phase II study
revealed marked uptake in the treated lesion [45].
Toxicity
Most investigators have evaluated the toxicity of SBRT
for liver oligometastases using the Common Termin-
ology Criteria for Adverse Events (CTCAE v3.0). Three
cases of fatal toxicity were recorded by the pioneers of
liver SBRT in patients with large hepatocellular carcin-
omas and pre-existing liver disease (ascites, jaundice, cir-
rhosis, or hepatitis C) [3]. No SBRT-related deaths were
reported in the studies we reviewed. In a study of 141
lesions with metastatic colorectal cancer including 69%
with liver oligometastases, there was a death from liver
failure in a patient receiving >10 Gy to 60% of the liver
(median: 14.4 Gy) and a colon perforation warranting
surgery [43].
Serious late SBRT-related complications are not un-
common. Late signs of liver fibrosis, portal hypertension,
ascites and bleeding from oesophageal vertices have
been described 28 and 41 months after irradiation of
two targets close to the liver hilum [42]. A patient with a
late episode of ascites (Grade 2) developed a portal
hypertension syndrome with melena (Grade 3) [44].
Other possible late sequels have been a case of thoracic
pain after irradiation of targets very close to the thoracic
wall and a case of rib fracture 10 months after irradi-
ation of a subcapsular liver metastasis located in the
vicinity of the ribs [42,48]. Early complications reported
by Mendéz et al. within 3 months of liver SBRT were
elevated gamma-glutamyltransferase (Grade 3) in 3
patients, asthenia (Grade 3) and liver toxicity (Grade 2)
in a previously treated patient (chemotherapy and resec-
tion) [44]. Ulcers and perforations were noted after de-
livery of >30 Gy in 3 fractions to the intestine [43].
Grade 3 gastritis and skin toxicity (oedema and break-
down) have also been reported [45]. Less serious adverseeffects ranged from 29% in one study (Grade 1 or 2
fever, chills or pain, nausea and vomiting) to 38% in an-
other (intermittent appetite or mild nausea, moderate
singulatus, and fever) [40,42].
SBRT of abdominal lymph node metastases (Local control
and toxicity)
The rationale of administering abdominal SBRT with
curative intent to patients with limited nodal metastatic
disease is the same as for selected patients with liver or
lung metastases. In the case of a single abdominal node, it
has been suggested that elective SBRT should incorporate
abdominal nodal chains and boosting pathological nodes.
This is because a common pattern of relapse of abdominal
lymph node (LN) metastases would seem to be within ad-
jacent LNs [51]. Incorporating adjacent retroperitoneal
(RP) LNs in the absence of concurrent distant progression
was based on the observation that, whereas 6 of 11 patients
with 22 oligometastases (19 abdomino-pelvic LNs) treated
by hypofractionated IGRT progressed in new para-aortic/RP
LNs outside the PTV, first failure in the other 5 patients
included adjacent RP LNs at/near midline within 1–2 verte-
bral bodies of the treated LNs [52]. In this study, Grade 3 GI
bleeding occurred in a patient with 3 periduodenal LNs re-
ceiving 3×8 Gy.
Six studies have investigated SBRT of abdominal LN
oligometastases in a total of 118 inoperable patients with
a variety of primary lesions (Table 5) [51,53-57]. There is
no consensus on optimal dose, number of fractions, or
planning constraints. The highest dose was 60 Gy; the
number of fractions ranged from 3 to 6. Median follow-
up was 12–28 months. PET-CT was used in 3 studies.
Organ motion was minimised with a vacuum pillow or
abdominal compression. In the largest study (41
patients), Bae et al. reported PFS, LC and OS rates for
18 colorectal cancer patients with LN metastases treated
by SBRT (45–51 Gy in 3 fractions) (Cyberknife™) and
followed up for a median of 28 months (range, 6–65)
[51]. Three-year rates were 40%, 64% and 60% respect-
ively, and 5-year rates were 40, 57% and 38%,
respectively.
A GTV of ≤17 ml and early radiological response and
were favourable predictive factors for LC. The 4-year LC
rate was significantly higher for complete responders vs
poor responders or non-responders (90% vs 24%,
p = 0.014) and in patients with a GTV of ≤17 mL
(P = 0.0059) [51,55]. In a univariate analysis, the number
of metastases was the only significant prognostic factor
identified for 2-year PFS) (41.7% (solitary) vs 0% (nonso-
litary), p <0.0004) [54].
In all 6 studies, three patients experienced serious ad-
verse effects (Grade 3 perforation after pelvic LN SBRT
(51 Gy) needing colostomy; 2 patients had Grade 4 in-
testinal obstruction of para-aortic LN SBRT (48 Gy)
Table 5 SBRT of abdominal lymph node oligometastases




et al. 2009 [53]
14 Prostate 33 (mean)× 3-5 Mean 18.6 - No in-field clinical progression
- Distant or regional LN progression
at mean time of 12.7 mo
- All patients with relapse had
high-risk disease
Bignardi et al. 2011 [54] 19 CRC (5/19) 45× 6 12 Actuarial rate of freedom from local
progression: 77.8 ± 13.9 at both 12
and 24 mos
Minimal acute and chronic toxicity
Choi et al. 2010 [55] 30 Uterus and cervix EBRT: 27–45 (n = 4 pts) 15 4-year LC rate: 67.4%
SBRT: 33–45× 3 (n = 24 pts) 4-year OS rate: 50.1%
(all 30 pts).
Kim et al. 2009 [56] 7 Gastric (salvage
aftersurgery)
48 (median)× 3 26 Complete response: n = 5
Partial response: n = 2
Kim et al. 2009 [57] 7 CRC Escalated dose 36–51× 3 26 Median survival: 37 mos
1-year OS: 100%
3-year OS: 71.4%
G4: intestinal obstruction in 1/7 patients
Bae et al. 2012 [51] 41 CRC 48(45 – 60)× 3 28 -PFS, LC and OS rates
3-year rates : 40%, 64%, 60%
5-year rates : 40, 57%, 38%
-G3 perforation after pelvic LN SBRT;G4
obstruction of para-aortic LN SBRT
EBRT: electron beam radiotherapy; CRC: colorectal cancer; LN: lymph node; LC: local control, OS: overall survival, G: grade.
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study (30 patients), 5 of the 25 patients receiving con-
comitant chemotherapy developed Grade 3 or higher
acute haematologic toxicity during chemotherapy [55].
One of the 30 patients developed a urethral stricture
20 months post-SBRT.
In brief, outcomes after SBRT for abdominal LN me-
tastases were similar to those obtained after surgery. Op-
timal normal tissue constraints and acceptable toxicity
have not yet been established.
SBRT of adrenal gland oligometastases
Adrenal gland metastases from non–small cell lung
carcinoma (NSCLC) are present in 5 to 10% of
patients at initial presentation. Surgical resection is
the main treatment option. In a review of 11 studies
in a total of 60 lung cancer patients who underwent
surgical resection of adrenal metastases, median sur-
vival was 14–24 months [58]. In patients with an iso-
lated adrenal metastasis, the 5-year OS rate ranged
from 10 to 23% [59]. However, according to Porte
et al., aggressive operative intervention is not indi-
cated in patients with a solitary synchronous contra-
lateral metastasis and operable NSCLC as thesemetastases are likely to be the first manifestation of
disseminateddisease because they develop mainly by
the haematogenous route. They prefer restaging
3 months after lung resection instead. If the metastasis
is homolateral to the primary lesion, a synchronous
complete removal can be performed without any added
morbidity or mortality [60]. For metachronous metas-
tases, a minimum 10-month interval between diagnosis
and resection of metastases is advocated to ensure that
there are no other metastatic sites. Patients with a
shorter interval between lung resection and adrenal
metastasis diagnosis may be amenable to RT or chemo-
therapy [61].
Clinical experience relating to SBRT of adrenal
metastases is limited. We retrieved 4 retrospective
studies in a total of 130 patients with a variety of
primary lesions, mostly NSCLC (Table 6) [62-65].
The highest dose was 50 Gy; the number of fractions
ranged from 3 to 10. Median follow-up was 9.8-
41 months. The low LC rate, reported by Chawla
et al. was due to the inclusion of 16/30 patients who
underwent SBRT for palliation or prophylactic palli-
ation of bulky adrenal metastases [62]. On the other
hand, the median OS of 23 months reported by Holy
Table 6 SBRT of adrenal gland metastases
Patients (N) Median dose (Gy) Median follow up
(mos)
Outcomes
Chawla et al., 2009 [62] 30 40 Gy (16–50)/4–10 fractions 9.8 At 1-year: survival: 44%, LC: 55%, distant
control rate, 13%
No late Grade ≥2 toxicity
Holy et al., 2011[63] 18 20-40 Gy/5 fractions 21 In 13 patients with isolated adrenal
metastasis: LC :77%, OS:23 months
Casamassima et al., 2012 [64] 48 36 Gy/3 fractionsa 16.2 At 1 and 2 years, LC: 90%; OS: 39.7%
and 14.5%, resp.
1 case of Grade 2 adrenal insufficiency
Scorsetti et al., 2012 [65] 34 32 Gy/4 fractions 41 At 1 and 2 years: LC 66% and 32%, resp.
No significant acute and late toxicities
a70% isodose, 17.14 Gy per fraction at the isocenter. Eight patients were treated with single-fraction (23 Gy) stereotactic radiosurgery.
Almaghrabi et al. Radiation Oncology 2012, 7:126 Page 8 of 10
http://www.ro-journal.com/content/7/1/126et al. for patients with an isolated adrenal metastasis
is similar to that for surgical resection [63]. Accord-
ing to Casamassima et al., SBRT may be considered
as an ablative therapy that is not influenced by fac-
tors such as the primary tumour, type of oligometa-
static adrenal disease (synchronous vs. metachronous,
unilateral vs bilateral) and PTV. Treatments were gener-
ally well tolerated. Definitive end-points for toxicity have
not been established. A case of Grade 2 adrenal insuffi-
ciency was reported by Casamassara et al. [64].
A retrospective comparison by matched case–control
study, of surgery (laparoscopic adrenalectomy) versus
SBRT (36 Gy in 5 fractions) of an isolated adrenal
oligometastases in patients with controlled primary
tumours revealed no significant difference in survival
at 6 months and 1 year (77% (95% CI: 49–100) and
62% (26–97), respectively, for SBRT and 87% (75–98)
and 77% (64–91) for LA) [66]. However, these find-
ings need to be confirmed in a prospective study with
longer term follow up.
In conclusion, SBRT may be an alternative to surgical
resection, especially for solitary adrenal metastases, and
displays a low toxicity profile. However, because toxicity
occurs late, close attention needs to be paid to the
length and quality of follow-up.
Looking ahead
Until fairly recently, RT of metastases was consid-
ered to be palliative only. The above recent advances
in imaging and biological targeting, however, provide
support for SBRT with curative intent in an oligome-
tastatic setting although, as yet, there is no consen-
sus on schedule (optimal doses, number of fractions,
and treatment delivery accuracy). The efficacy of
SBRT is well established for liver oligometastases but
less well established, although promising, for abdom-
inal LN metastases (one 5-year study) and adrenal
gland oligometastases (survival similar to surgicalresection for solitary adrenal metastases). Further
prospective studies are needed to confirm these
results.
SBRT is more effective in the case of “de novo oligo-
metastases” than widespread metastases. A state of
“induced oligometastases” needs effective systemic ther-
apy to eradicate most metastatic sites. Emphasis should
therefore be placed on the criteria needed for effective
patient selection and on delivery of appropriate therapy.
Approaches such as microRNA detection have shown
promise in patient selection.
Distant metastases are the main cause of death
after SBRT. Chemoradiotherapy thus deserves study.
Chemotherapy increases organ sensitivity to radiation
and also kills tumour cells disseminated in the blood.
Promising antitumour responses without potentiation
of RT toxicity were observed in a Phase I study of
concurrent sunitinib and hypofractionated IGRT fol-
lowed by maintenance sunitinib in patients with oli-
gometastases [67]. A multi-institutional Phase II trial
is ongoing. In 2007, we initiated a Phase II prospect-
ive multicentre study of SBRT and concurrent irinote-
can in colorectal cancer patients with unresectable
liver and lung metastases. As preliminary results for
the combination did not differ significantly from
those for SBRT alone, we increased the tumoricidal
dose in order to achieve higher LC [68]. The study is
ongoing.
In conclusion, published studies suggest that SBRT
is a valuable alternative to surgery in patients with
liver or abdominal lymph node oligometastases al-
though no SBRT standards have yet been defined for
the latter. The value of SBRT in the treatment of ad-
renal oligometastases will depend on their early de-
tection. Future attempts to improve outcomes could
focus on including a SBRT plus chemotherapy arm
in SBRT trials and identifying patients with oligome-
tastatic disease by microRNA expression.
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